Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Acumen's Alzheimer drug falls short. Acumen Pharmaceuticals announced that sabirnetug (ACU193), an antibody targeting toxic amyloid beta oligomers, failed to meet its primary endpoint in the phase 2 ALTITUDE-AD trial across 542 early Alzheimer's patients. With no meaningful benefit over placebo on cognitive and functional decline, Acumen is discontinuing the entire program.
Acumen's Alzheimer drug falls short. Acumen Pharmaceuticals has announced that sabirnetug (ACU193) — an investigational antibody designed to target toxic amyloid beta oligomers — failed to meet its primary endpoint in the phase 2 ALTITUDE-AD trial. The trial enrolled 542 participants with early Alzheimer's disease (mild cognitive impairment or mild dementia) across sites in the US, Canada, the EU, and the UK. Participants received sabirnetug infusions at 35 mg/kg or 50 mg/kg, or placebo, every four weeks for 18 months.
The drug showed no meaningful difference from placebo on the primary measure of cognitive and functional decline (iADRS), and key secondary endpoints like the CDR-SB also fell short. Acumen is now halting the program entirely — including its open-label extension — and will explore strategic options, including its Enhanced Brain Delivery platform.
By the Numbers:
Why it matters: Sabirnetug was designed as a differentiated approach — targeting soluble amyloid oligomers rather than plaques directly, with a potentially lower ARIA risk. Its failure adds to a growing list of Alzheimer's drug setbacks and raises fresh questions about whether oligomer-targeting is a viable therapeutic strategy.
